Background. The manner in which ribavirin (RBV) enhances the antiviral effects of interferon (IFN) against hepatitis C virus (HCV) remains unknown. We investigated whether RBV modifies IFN-stimulated genes (ISGs) in vivo and in vitro.
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, infecting about 170 million individuals worldwide [1] . Although ribavirin (RBV) plus pegylated interferon (IFN)-a has become a standard treatment for patients with chronic hepatitis C, this therapy eliminates HCV in only up to 60% of infected individuals [2, 3] . RBV (1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a guanosine analogue with a broad range of antiviral activity against several RNA and DNA viruses [4] . This effect has transferred over into clinical applications against respiratory syncytial virus infection [5] . Of note, RBV together with IFN-a is used to treat HCV infection [3] . Since the discovery of RBV 30 years ago, various proposed mechanisms of action have included the inhibition of HCV RNA-dependent RNA polymerase [6] , promotion of the Th1 immune response [7] , inhibition of inosine-5-monophosphate dehydrogenase [8, 9] , and mutagenesis leading to error catastrophe [10, 11] . However, the precise mechanism of how RBV acts against HCV remains undefined. Although some evidence supports these anti-HCV actions of RBV in vitro, RBV monotherapy only minimally impacts chronic hepatitis C infection in the clinical setting [12, 13] . That is, RBV can only eliminate HCV when combined with IFN.
IFN stimulates a large number of genes called IFNstimulated genes (ISGs) that mediate its anti-HCV effects. Moreover, host liver cells can produce autocrine IFN-b through the pathways of Toll-like receptors induced by pathogens as a defense strategy [14] . The production of IFN is thought to be essential for protection against viral infections. Some ISGs, such as protein kinase R (PKR), myxovirus resistance protein A (MxA), and 2#-5#-oligoadenylate synthase (OAS) have powerful antiviral effects against HCV [15] . In particular, PKR activated (phosphorylated) by IFN phosphorylates eukaryotic initiation factor-2 subunit alpha (eIF-2a), which in turn stops protein synthesis and exerts antiviral effects [16] .
Because the additive anti-HCV effects of RBV are clinically obvious [3] , we postulated that RBV would enhance the antiviral effects of IFNs through ISGs. We thus investigated the mechanism of how RBV enhances ISGs.
MATERIALS AND METHODS

Patients and Blood Samples
Peripheral blood T lymphocytes were isolated from patients with chronic hepatitis C with use of the Pan T cell isolation kit II (Miltenyi Biotec) according to the manufacturer's protocol. The patients were treated with either peg-IFN-a combined with RBV (n 5 53) or peg-IFN-a alone (n 5 12). Supplementary Table 1 shows the clinical features of the patients. All enrolled participants provided written informed consent to research testing under protocols approved by the institutional review boards of Ehime University (approval number 0710004). The study protocol conformed to the ethical guidelines of the Declaration of Helsinki.
Cell Lines, Infection, and Transfection
The human hepatoma cell lines Huh7, HepG2 (American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (Invitrogen).
We used the plasmid-based binary HCV replication system [17, 18] , in which the plasmid harbored an infectious full-length genotype 1a cDNA sequence corresponding to the H77 prototype strain [19] , to yield pT7-flHCV-Rz (pH77; provided by Dr Raymond T. Chung). We transfected Huh7 and HepG2 using 3 lg of pH77 and Lipofectamine (Invitrogen) as described elsewhere [17, 18] . The cells were infected with a replication-defective adenovirus vector containing T7 polymerase (Ad-T7pol) at a multiplicity of infection of 10 at 24 hours after transfection.
We used the pJFH1-full (provided by Dr Takaji Wakita) HCV replication system encoding the HCV genotype 2a sequence in vitro [20] . Huh7 cells were resuspended in Opti-MEM I (Invitrogen) containing 10 lg of HCV RNA and electrically pulsed at 960 microfarads and 260 volts using a Gene Pulser II (Bio-Rad) for RNA transfection.
We added 100 IU/mL IFN-a (Schering-Plough) and/or 50 lM RBV (Sigma-Aldrich) as described elsewhere [10, 16, 17] . The expression of T7 polymerase was not remarkably altered by IFN-a and/or RBV (Supplementary Figure 1) .
RNA Interference and Antibody Neutralization of IFN-b
Cells were transfected with 20 nM of a small interfering RNA (siRNA) targeting IFN-b or with a scrambled control siRNA (Invitrogen) using Lipofectamine RNAiMax (Invitrogen) at 1 day before transfection with pH77, as described elsewhere [18] .
We neutralized IFN-b by adding 1.0 lg/mL of anti-human IFN-b antibody or isotype control antibody (R&D Systems) to the culture medium at 3 hours after infection and then incubated the cells for 48 hours as described elsewhere [18] .
Quantitative Real-time Reverse-Transcription Polymerase Chain Reaction Cellular RNA was extracted using TRIzol (Invitrogen) and digested with DNase I using a DNA free-kit (Ambion) according to the manufacturer's protocol. Cellular messenger RNA (mRNA) was quantified using the reverse transcription of 1 lg of isolated RNA using rTth or an oligo d(T) 16 (Invitrogen) primer under standard conditions [10] . Real-time polymerase chain reaction (PCR) amplification proceeded using LightCycler technology (Roche Diagnostics) and SYBR green I dye, as described elsewhere [16] . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), IFN-b, OAS, MxA, and interleukin 8 (IL-8) (Search LC) were detected using primer sets under the recommended conditions. Real-time PCR amplification of HCV RNA and PKR proceeded as described elsewhere [16] . Data are expressed as copy numbers of HCV RNA or cellular mRNA per molecule of GAPDH mRNA.
Western Blotting
Protein extracted from cells was lysed with 100 lL of RIPA buffer [16] . Concentrations of extracted proteins in lysates were measured using the DC protein assay kit (Bio-Rad), and 30 lg of lysate was loaded in 4%-12% Bis-Tris gradient gels (Invitrogen).
Proteins of interest were detected using antibodies to human PKR, eIF-2a (Santa Cruz Biotechnology), phosphorylated PKR (Invitrogen), phosphorylated eIF-2a (Cell Signaling Technology), T7 RNA polymerase (Novagen), and actin (Chemicon International), as well as species-specific conjugated secondary antibodies derived from kits (GE Healthcare).
Enzyme-Linked Immunosorbent Assay of IL-8 and HCV Core Protein
Concentrations of IL-8 were measured in cultured cell lysates (0.2 mg/mL) in RIPA buffer using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems) according to the manufacturer's instructions. HCV core antigen in cell lysates (0.2 mg/mL) were quantified using HCV core antigen ELISA kits (Ortho-Clinical Diagnostics) [16] . The lower limits of detection for IL-8 and for HCV were 31.2 pg/mL and 44.4 fmol/L, respectively. All assays proceeded in duplicate.
PCR Array for Genes Related to IL-8 Transcription
We isolated and confirmed the quality of RNA and then performed PCR array analyses using Transcription PCR Array kits (Qiagen) according to the manufacturer's instructions. All individual experiments were performed 3 times, and data were analyzed using the recommended programs. Significant changes were identified in DCt (threshold cycle) data using Student t test. [21, 22] , together with a control reporter plasmid conjugated with Renilla luciferase reporter constructs (phRL-TK Int-; Promega). Luciferase activities in the samples were measured 48 hours later using the DualLuciferase Reporter Assay System (Promega) and a luminometer (Micro-Tec). The level of transcription was evaluated as the ratio of firefly luciferase to renilla luciferase.
Statistical Analysis
All values are expressed as means and standard error (SE). Data were statistically analyzed using JMP, version 8.0 (SAS Institute).
Differences in mean values were analyzed using the Wilcoxon test. P values of ,.05 were considered statistically significant.
RESULTS
IFN-a Enhanced ISGs More With Than Without RBV in Patients Infected With HCV
We examined the effect of RBV combined with peg-IFN-a by measuring the time course of ISG mRNA levels in T lymphocytes isolated from peripheral blood mononuclear cells (PBMCs) collected from patients before and after therapy with IFN-a and/or RBV. Levels of PKR mRNA were significantly enhanced by the combination compared with IFN-a alone (mean 6 SE at 4 hours, 668.5 6 149.9 vs 132.5 6 51.5; P , .05) ( Figure 1 ). Moreover, MxA mRNA was upregulated at 4 hours after the combination was administered (mean 6 SE, 0.76 6 0.15 vs 0.33 6 0.18; P , .05). However, OAS mRNA was not significantly changed. Mean levels of IL-8 mRNA were higher in patients treated with IFN-a and RBV than in those given IFN-a alone. However, the difference did not reach significance. The combination RBV and IFN-a rapidly 
IFN-a and RBV Suppress HCV Replication
We assayed the effects of RBV combined with IFN-a in vitro. The response to autocrine IFN-b is somewhat incomplete in Huh7 cells that are used with major HCV replication systems [23] . Therefore, we investigated the anti-HCV mechanisms of RBV using a plasmid-based HCV replication system in the hepatocyte-derived cell lines HepG2 (pH77-HepG2) and Huh7 (pH77-Huh7), as well as in JFH-1 cells derived from Huh7 cells that are generally used to study HCV replication. We added IFN-a and/or RBV to these cells. IFN-a, RBV, and a combination of both each diminished HCV RNA levels ( Figure 2A ) and diminished the expression of HCV core proteins ( Figure 2B ). PKR nor MxA, both of which were additively upregulated by RBV, was identified in either pH77-Huh7 or JFH-1 cells. We also assayed PKR and its related proteins to determine how RBV and IFN-a modulate their activities ( Figure 2C ). RBV and IFN-a alone and in combination elicited PKR overexpression in the 3 cell lines. The expression of PKR and of phosphorylated PKR (activated form of PKR) was most upregulated in pH77-HepG2 cells by RBV plus IFN-a rather than by either alone. Moreover, phosphorylated eIF-2a, which indicates activated PKR function, was most upregulated by RBV plus IFN-a in pH77-HepG2 cells. These data indicate that PKR and its activation are additively upregulated by RBV when combined with IFN-a rather than by IFN-a alone in pH77-HepG2 cells.
On the other hand, RBV upregulated IL-8 mRNA (Figure 2A ), and unlike other ISGs, RBV further upregulated IL-8 mRNA when combined with IFN-a. We measured the amount of IL-8 protein expressed in cell lysates using ELISA ( Figure 2D 
The RBV-induced upregulation of ISGs was more evident in pH77-HepG2 than in either pH77-Huh7 cells or in JFH-1 cells derived from Huh7 cells. We therefore investigated the effect of autocrine IFN-b in pH77-HepG2 cells, because the response of Huh7 cell lines to this cytokine is impaired. 
IFN-a and RBV
Enhanced Autocrine IFN-b in HepG2 Cells Autocrine IFN-b was significantly upregulated by RBV plus IFN-a, compared with IFN-a alone in pH77-HepG2 cells (4.3 3 10 25 6 0.3 3 10 25 vs 2.7 3 10 25 6 0.2 3 10 25 on day 2 [P , .05] and 2.1 3 10 25 6 0.3 3 10 25 vs 0.6 3 10
Knockdown of IFN-b Diminished the Additive Effects of RBV Plus IFN-a
We examined the effects of IFN-b inhibition to determine whether the upregulation of ISGs by RBV depends on an increase in autocrine IFN-b. We used pH77-HepG2 cells at day 2 after adding reagents, because ISGs were significantly upregulated with autocrine IFN-b enhancement under these conditions. Autocrine IFN-b was downregulated by .90% by IFN-b siRNA in the presence of IFN-a, RBV, or both ( Figure 3A) . We further assessed the modulation of ISG mRNAs via IFN-b mRNA downregulation. IFN-a continued to upregulate PKR and MxA after IFN-b siRNA downregulation. The additive upregulation of PKR and MxA by RBV plus IFN-a was diminished ( Figure 3B ). These results indicated that the upregulation induced by RBV depends on its ability to increase autocrine IFN-b.
The additive upregulation of IL-8 induced by RBV plus IFN-a was diminished, compared with that induced by IFN-a alone. However, RBV continued to obviously upregulate IL-8, compared with the absence of RBV ( Figure 3B ). This behavior differed from that of other ISGs and suggested that RBVinduced IL-8 upregulation partly depends on autocrine IFN-b. However, the main mechanism of RBV-induced IL-8 upregulation does not depend on autocrine IFN-b. 
IL-8 Is Enhanced by RBV Through AP-1 Signaling
The ELISA results showed that RBV increased IL-8 expression in both pH77-HepG2 and pH77-Huh7 cells ( Figure 4A ), but to a greater extent in the former. The results of luciferase assays using a reporter construct of the promoter region of the IL-8 gene confirmed that RBV dose-dependently upregulated the level of IL-8 transcription, thus confirming a direct effect of RBV ( Figure 4B ). We examined the mechanism of RBV-induced IL-8 upregulation using a PCR array for transcription factors (Supplementary  Table 2 ) and identified genes associated with the IL-8 promoter ( Figure 4C) . RBV upregulated the AP-1-related genes c-Jun, c-Fos, JunB, JunD, and ATF3, but not CEBPB or NF-jB.
We further analyzed the mechanism of RBV-induced IL-8 upregulation. The results of the luciferase assays using reporter constructs with or without mutations in the AP-1, CEBPB, and NF-jB sites confirmed that AP-1 is responsible for RBV-induced IL-8 transcriptional upregulation ( Figure 4D ).
DISCUSSION
IFN is considered to be essential for eliminating HCV, and RBV has additive anti-HCV effects only when combined with IFN-a. Here, we investigated modifications of the ISGs (PKR, MxA, OAS, and IL-8) that are reportedly associated with HCV replication to determine how RBV plus IFN-a affects HCV. We found that RBV upregulates PKR activity as well as MxA and IL-8 expression through enhancing autocrine IFN-b. Moreover, RBV significantly upregulated IL-8 without IFN-a, which is responsible for AP-1 upregulation. The benefits and disadvantages of ISG modification by RBV must be understood before HCV can be eliminated with or without IFN. Moreover, such understanding might lead to a discovery of novel and more-powerful RBV-like compounds against HCV.
Our findings in vivo showed that RBV upregulates PKR and MxA mRNA in peripheral T lymphocytes from HCV-infected patients treated with IFN-a. These findings are compatible with a report describing that RBV induces ISGs in the human liver and in PBMCs [24] . The ISGs in PBMCs could be predictive factors for evaluating the effectiveness of anti-HCV therapy [24, 25] . However, this strategy is somewhat limited, because ISG expression and/or mechanisms regulating ISG expression might differ between PBMCs and liver cells [26] . We were also concerned that the PBMC population might be altered during IFN-based therapy. We therefore isolated T lymphocytes for this analysis. However, the significantly different distribution of the HCV genotype in patients with or without RBV still imposed limitations. We confirmed the alterations of ISGs by IFN and/or RBV using assays of hepatocytes in vitro because of these limitations.
Thomas et al found that RBV induced ISGs in a culture model comprising the JFH-1 HCV genotype 2a strain and the Huh7.5.1 cell line [27] . We also used the JFH-1 strain with Huh7 cell lines and the H77 HCV genotype 1a strain with Huh7 and HepG2 cell lines. The additive upregulation of autocrine IFN-b was evident in HepG2 cells with H77 but undetectable in Huh7 cells with JFH-1 and H77. Our findings from a replication system using HepG2 cell lines indicated that RBV upregulates some ISGs through IFN-b enhancement. The basis for HCV replication permissiveness in Huh7 and Huh7.5.1 cells has not been fully explained. However, it might be associated with a low response of autocrine IFN-b induction triggered by viral double-stranded RNA (dsRNA) [28] and insufficient expression of Toll-like receptor 3, which recognizes dsRNA [29] . Therefore, interactions between host cellular proteins and HCV using systems based strictly on Huh7 and Huh7.5.1 cells might be confounded by the relative IFN-b deficiency in these cells. The pH77-based HCV expression system permitted HCV replication in both Huh7 and HepG2 cells. We found that autocrine IFN-b and ISGs are more upregulated in HepG2 than in Huh7. We then examined the roles of RBV in the regulation of these factors in The upregulation of PKR and MxA through IFN-b enhancement will be important for the anti-HCV effects of RBV, but RBV also dose-dependently elevated IL-8 in a process that partially depends on the enhancement of autocrine IFN-b. However, the main mechanism of IL-8 enhancement was independent of autocrine IFN-b. IL-8 is a chemokine that serves as a chemical signal to attract neutrophils at sites of inflammation, and therefore, it is also known as neutrophil chemotactic factor [31] . One possible benefit of RBV-induced IL-8 upregulation is that neutrophils recruited by IL-8 would phagocytose target antigens, which would trigger Toll-like receptors and result in increased autocrine IFN-b and ISG production in vivo. On the other hand, the negative regulation of anti-HCV activity by IL-8 [32] suggests that the upregulation of IL-8 induced by RBV would not benefit HCV elimination [33, 34] . Moreover, IL-8 is related to inflammation including viral hepatitis and would increase oxidant stress [35] , which might weaken the effects of anti-HCV drugs. Whether the IL-8 upregulation by RBV would positively or negatively affect the anti-HCV activity of IFN in the body should be evaluated in a future study in vivo that would include the immune systems.
Autocrine IFN-b partially affected RBV-induced IL-8 enhancement, but it mostly depended on the activation of transcription by AP-1, and not by NF-jB or CEBPB. Activator protein-1 is a family of transcription factors comprising homodimers or heterodimers of Jun and Fos or activating transcription factor proteins [36] . Jun-Jun and Jun-Fos dimers preferentially bind to the phorbol 12-O-tetradecanoate-13-acetate-responsive element located in the IL-8 promoter.
The results of the PCR array showed that RBV upregulates the Fos and Jun families. These AP-1 proteins are regulated by mitogen-activated protein kinases, which in turn are partially regulated by Toll-like receptor signaling pathways [36] . To clarify the role of RBV-induced AP-1 activation in the context of HCV infection would be a target of further investigation.
In summary, we showed that RBV additively upregulates PKR and MxA through enhancing autocrine IFN-b and IL-8 through AP-1 activation. These properties of RBV could both positively and negatively affect HCV elimination. Understanding the precise effects of RBV in the liver infected with HCV would be essential to developing a suitable therapeutic strategy with which to eliminate HCV in the clinical setting.
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